- 1.
Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98–108. [PubMed][CrossRef]
- 2.
He A, Merkel B, Brown JWL et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 2020; 19: 307–16. [PubMed][CrossRef]
- 3.
Brown JWL, Coles A, Horakova D et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321: 175–87. [PubMed][CrossRef]
- 4.
Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol 2016; 23 (suppl 1): 18–27. [PubMed][CrossRef]
- 5.
Helsedirektoratet. Nasjonal faglig retningslinje for diagnostikk, attakk- og sykdomsmodifiserende behandling av multippel sklerose. https://www.helsedirektoratet.no/retningslinjer/multippel-sklerose Lest 24.3.2021.
- 6.
Piehl F. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. J Intern Med 2020; joim.13215. [PubMed][CrossRef]
- 7.
Holmøy T, Torkildsen Ø. Familieplanlegging, graviditet og amming ved multippel sklerose. Tidsskr Nor Legeforen 2016; 136: 1726–9. [PubMed][CrossRef]
- 8.
Dobson R, Hellwig K. Use of disease-modifying drugs during pregnancy and breastfeeding. Curr Opin Neurol 2021; Publish Ahead of Print. doi: 10.1097/WCO.0000000000000922. [PubMed][CrossRef]
- 9.
Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord 2020; 45: 102439. [PubMed][CrossRef]
- 10.
Sykdomsbegrensende legemidler for behandling av attakkpreget multippel sklerose, inkludert rituximab. En metodevurdering. Oslo: Folkehelseinstituttet, 2019. https://www.fhi.no/publ/2019/sykdomsbegrensende-legemidler-for-behandling-av-attakkpreget-multip-pel-skl/ Lest 8.2.2021.
- 11.
Comi G, Dalla Costa G, Moiola L. Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials? Expert Rev Neurother 2021; 21: 21–34. [PubMed][CrossRef]
- 12.
Myhr KM, Torkildsen Ø, Lossius A et al. B cell depletion in the treatment of multiple sclerosis. Expert Opin Biol Ther 2019; 19: 261–71. [PubMed][CrossRef]
- 13.
Dunn N, Juto A, Ryner M et al. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Mult Scler 2018; 24: 1224–33. [PubMed][CrossRef]
- 14.
Berger T, Adamczyk-Sowa M, Csépány T et al. Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. Ther Adv Neurol Disorder 2020; 13: 1756286420975223. [PubMed][CrossRef]
- 15.
Holmøy T, Fevang B, Olsen DB et al. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC Res Notes 2019; 12: 497. [PubMed][CrossRef]
- 16.
Luna G, Alping P, Burman J et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 2020; 77: 184–91. [PubMed][CrossRef]
- 17.
Ryerson LZ, Foley J, Chang I et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 2019; 93: e1452–62. [PubMed][CrossRef]
- 18.
Peeters LM, Parciak T, Walton C et al. COVID-19 in people with multiple sclerosis: A global data sharing initiative. Mult Scler 2020; 26: 1157–62. [PubMed][CrossRef]
- 19.
Harding K, Williams O, Willis M et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 2019; 76: 536–41. [PubMed][CrossRef]
- 20.
Hauser SL, Cree BAC. Treatment of multiple sclerosis: A review. Am J Med 2020; 133: 1380–1390.e2. [PubMed][CrossRef]
- 21.
Boremalm M, Sundström P, Salzer J. Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis. J Neurol 2021 doi: 10.1007/s00415-021-10399-8. [PubMed][CrossRef]
- 22.
Kvistad SAS, Lehmann AK, Trovik LH et al. Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. Mult Scler 2020; 26: 1889–97. [PubMed][CrossRef]
- 23.
Årsrapport. 2019. Bergen: Norsk multippel sklerose register og biobank, 2020. https://www.kvalitetsregistre.no/sites/default/files/21_arsrapport_2019_norsk_ms_register.pdf Lest 8.2.2021.
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.
Skjev drøfting
13.05.2021Det er bra at forfatterne av denne kronikken vil starte behandling med de mest effektive bremsemedisinene fra diagnosetidspunktet. Men jeg mener at de motsier seg selv ved å si at et aktuelt unntak er tilfeller «der mange års observasjonstid siden symptomdebut…